95504-02-2Relevant academic research and scientific papers
Synthesis and evaluation of 2′-dihalo ribonucleotide prodrugs with activity against hepatitis C virus
Chris Krueger,Chen, Hui-Ju,Randolph, John T.,Brown, Brian S.,Halvorsen, Geoff T.,Heyman, Howard R.,Li, Tongmei,Marvin, Christopher C.,Shanley, Jason P.,Voight, Eric A.,Bow, Daniel A.J.,Van Handel, Cecilia,Peterkin, Vincent,Carr, Robert A.,Stolarik, DeAnne,Dekhtyar, Tatyana,Irvin, Michelle L.,Krishnan, Preethi,Henry, Rodger F.,Wagner, Rolf,DeGoey, David A.
supporting information, (2019/11/26)
[Figure presented] Hepatitis C virus (HCV) nucleoside inhibitors have been a key focus of nearly 2 decades of HCV drug research due to a high barrier to drug resistance and pan-genotypic activity profile provided by molecules in this drug class. Our investigations focused on several potent 2′-halogenated uridine-based HCV polymerase inhibitors, resulting in the discovery of novel 2′-deoxy-2′-dihalo-uridine analogs that are potent inhibitors in replicon assays for all genotypes. Further studies to improve in vivo performance of these nucleoside inhibitors identified aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs 18a and 18c, which provide high levels of the active triphosphate in dog liver. AIBEE prodrug 18c was compared with sofosbuvir (1) by co-dosing both compounds by oral administration in dog (5 mg/kg each) and measuring liver concentrations of the active triphosphate metabolite at both 4 and 24 h post dosing. In this study, 18c provided liver triphosphate concentrations that were 6-fold higher than sofosbuvir (1) at both biopsy time points, suggesting that 18c could be a highly effective agent for treating HCV infected patients in the clinic.
A general and enantioselective approach to pentoses: A rapid synthesis of PSI-6130, the nucleoside core of sofosbuvir
Peifer, Manuel,Berger, Rapha?lle,Shurtleff, Valerie W.,Conrad, Jay C.,Macmillan, David W. C.
supporting information, p. 5900 - 5903 (2014/05/20)
An efficient route towards biologically relevant pentose derivatives is described. The de novo synthetic strategy features an enantioselective α-oxidation reaction enabled by a chiral amine in conjunction with copper(II) catalysis. A subsequent Mukaiyama aldol coupling allows for the incorporation of a wide array of modular two-carbon fragments. Lactone intermediates accessed via this route provide a useful platform for elaboration, as demonstrated by the preparation of a variety of C-nucleosides and fluorinated pentoses. Finally, this work has facilitated expedient syntheses of pharmaceutically active compounds currently in clinical use.
